# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
-SEC Filing
JMP Securities analyst Reni Benjamin initiates coverage on Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform ratin...
HC Wainwright & Co. analyst Robert Burns downgrades Prelude Therapeutics (NASDAQ:PRLD) from Buy to Neutral and announces...
First-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-concept...
Morgan Stanley analyst Jeffrey Hung downgrades Prelude Therapeutics (NASDAQ:PRLD) from Equal-Weight to Underweight and lower...
On December 11, 2023, Prelude Therapeutics Incorporated, a Delaware corporation (the "Company"), entered into a securit...
HC Wainwright & Co. analyst Robert Burns maintains Prelude Therapeutics (NASDAQ:PRLD) with a Buy and lowers the price ta...